Health state utility values for patients with type 2 diabetes in China: A systematic review and meta-analysis
Authors' conclusion
This study provides a comprehensive synthesis of HSUVs for patients with T2DM in China, offering policymakers a nuanced understanding of HSUV heterogeneity to support the development of more targeted and effective healthcare interventions.
Study context
- Population
- Patients with T2D in mainland China, incl. related complications and comorbidities35 studies
- Outcome
- Pooled health state utility value (HSUV)
Methodological detailsrandom-effects model, PRISMA, Search of five major databases up to April 2025, Quality assessed with a four-item tool adapted for HSUV studies
- Random-effects model
- PRISMA
- Search of five major databases up to April 2025
- Quality assessed with a four-item tool adapted for HSUV studies
Pooled result
As reported in the abstract
Pooled HSUV, T2D
Pooled HSUV for patients with T2D
0.867
95% CI 0.841–0.894
Further pooled results
HSUV with diabetes-related complications and comorbidities
- Complications and comorbidities markedly reduced utility values; HSUV range
- 0.673 to 0.828
HSUV by valuation instrument
- Lowest, SF-6D
- 0.725
- Highest, 15D
- 0.968
- EQ-5D-3L most commonly used instrument; considerable variation across instruments
Original publication
Health state utility values for patients with type 2 diabetes in China: A systematic review and meta-analysis. Diabetes Res Clin Pract. Published 30 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →